Recombinant KRT17 anticorps

N° du produit ABIN7881374

Cet anticorps anti-KRT17 Monoclonal Lapin (Clone KRT17-8320R) (ABIN7881374) détecte spécifiquement KRT17 dans IHC (p). L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour Recombinant KRT17 anticorps (ABIN7881374)

Antigène: KRT17 (Keratin 17 (KRT17))

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Lapin

Clonalité: Monoclonal

Conjugué: Cet anticorp KRT17 est non-conjugé

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Classe de qualité: Carrier-free

Clone: KRT17-8320R

Détail du produit anti-KRT17 anticorps

Fonction: Recombinant Cytokeratin 17 Antibody / KRT17 (azide and preservative free)

Purification: Protein A/G affinity

Immunogène: A recombinant fragment of the human protein was used as the immunogen for the recombinant Cytokeratin 17 antibody.

Isotype: IgG, kappa

Information d'application

Indications d'application: Optimal dilution of the recombinant Cytokeratin 17 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: -20 °C

Stockage commentaire: Aliquot the recombinant Cytokeratin 17 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur KRT17

Antigène: KRT17 (Keratin 17 (KRT17))

Autre désignation: Cytokeratin 17

Sujet: Cytokeratin 17 (CK17) is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands, such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. Additionally, anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

UniProt: Q04695